BIORCHESTRA
BIORCHESTRA is dedicated to developing innovative medicines to improve patients' lives, focusing on transformational RNA medicines and delivery systems for neurodegenerative and rare CNS diseases. They aim to solve major unmet medical needs through their pioneering research and technology platform.
Industries
Nr. of Employees
medium (51-250)
BIORCHESTRA
Korea Headquarters: 1, Gukjegwahak 2-ro, Yuseong-gu, Daejeon, 34000, South Korea
Patents
Products
Lead RNA therapeutic program (BMD-001)
Lead RNA therapeutic program focused on neurodegenerative disease indications, including Parkinson's disease; progressed through preclinical development and presented data at scientific meetings.
Targeting technology platform for CNS delivery (BDDS-style platform)
A platform designed to enable targeted delivery of nucleic acid therapeutics to the brain/central nervous system for improved tissue targeting.
Lead RNA therapeutic program (BMD-001)
Lead RNA therapeutic program focused on neurodegenerative disease indications, including Parkinson's disease; progressed through preclinical development and presented data at scientific meetings.
Targeting technology platform for CNS delivery (BDDS-style platform)
A platform designed to enable targeted delivery of nucleic acid therapeutics to the brain/central nervous system for improved tissue targeting.
Services
Research partnerships and option/licensing agreements to apply targeting and delivery technologies in joint programs.
Research partnerships and option/licensing agreements to apply targeting and delivery technologies in joint programs.
Expertise Areas
- RNA therapeutics development
- CNS-targeted drug development
- Target discovery and translational research
- Nanomedicine and polymer formulation
Key Technologies
- RNA therapeutics
- siRNA
- CNS-targeted delivery platforms
- Nanoparticle/nanomedicine delivery
News & Updates
Announcement of the upcoming shareholder meeting scheduled for March 16, 2025.
Participation in the BIO USA 2024 event with a session on RNA therapeutics.
Announcement of the shareholder meeting scheduled for March 14, 2024.
Participation in the summit discussing brain target delivery of RNA therapeutics.
Grand Prize winner of the 2023 Merck Advanced Biotech Grant program
BIORCHESTRA was awarded the grand prize in the Merck Advanced Biotech Grant program, recognizing their innovative contributions.
Participation in D- Unicorn project organized by Daejeon Metropolitan City, South Korea
BIORCHESTRA was selected to participate in the prestigious D- Unicorn project, an opportunity supported by the city of Daejeon.
Announcement of the upcoming shareholder meeting scheduled for March 16, 2025.
Participation in the BIO USA 2024 event with a session on RNA therapeutics.
Announcement of the shareholder meeting scheduled for March 14, 2024.
Participation in the summit discussing brain target delivery of RNA therapeutics.
Grand Prize winner of the 2023 Merck Advanced Biotech Grant program
BIORCHESTRA was awarded the grand prize in the Merck Advanced Biotech Grant program, recognizing their innovative contributions.
Participation in D- Unicorn project organized by Daejeon Metropolitan City, South Korea
BIORCHESTRA was selected to participate in the prestigious D- Unicorn project, an opportunity supported by the city of Daejeon.